Record numbers of patients are seeking out medicinal cannabis as a treatment, with Cannatrek the market leader in Australia, according to the latest retail pharmacy data from NostraData.

The figures reveal a 130% increase in patients receiving medicinal cannabis from pharmacies in the last quarter of 2021, compared to the same period in 2020, while prescriber numbers were up 47% and dispensing pharmacies increased by 35%.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...

Join the Conversation

3 Comments

  1. Hi Shaun

    Here’s the response from Mike da Gama at NostraData…

    Re: The latest info I can see re. NostraData is that they are collecting data from 4,800 of Australia’s pharmacies (not the full complement of approx 6,000) – is this still correct?

    Yes, that is correct. This group of pharmacies has proven to be representative of the whole market. We have kept to actual counts in this report to allow for comparative reporting in the future and given there is no consensus data available, it will be difficult to validate an estimate for the full 5,800 pharmacies’ true sales.

    Re: Would also be keen to understand why they have provided patient numbers and not product numbers (the traditional way that data providers in the pharmaceutical industry do)?

    As per the previous answer, but more importantly, traditional data providers report on product numbers because they don’t have access to patient quantitative data. Patient breadth is more indicative of product adoption than product volume alone. We also report on volume when the story is about the performance of individual products rather than prescriber and patient behaviour.

    I hope that helps.

    Mike

  2. The latest info I can see re. NostraData is that they are collecting data from 4,800 of Australia’s pharmacies (not the full complement of approx 6,000) – is this still correct?
    Would also be keen to understand why they have provided patient numbers and not product numbers (the traditional way that data providers in the pharmaceutical industry do)?
    Shaun

    1. Thanks for the questions Shaun. I’ve contacted NostraData and will post their reply when I hear back.

      Cheers

      Martin, Cannabiz